243. Bull, Bear & Beyond – Basilea Pharmaceutica: executive interview

In this interview, we speak with Basilea Pharmaceutica CEO David Veitch and CFO Adesh Kaul about the strategy driving one of the world’s leading pure-play anti-infectives companies. They discuss Basilea’s differentiated business model, how disciplined in-licensing, strategic partnering and non-dilutive R&D funding support from government agencies have underpinned its long-term success, and why the company continues to strengthen its position in anti-infectives. David also outlines Basilea’s key strategic priorities, including advancing the Phase III programmes for fosmanogepix and ceftibuten ledaborbactam, while Adesh highlights the commercial and clinical milestones investors should watch over the coming months, the continuing role of acquisitions and in-licensing in strengthening the portfolio, and why he believes Basilea’s long-term value proposition remains underappreciated by the market.

**************************************************************************************

About ‘Bull, Bear & Beyond’

Bull, Bear & Beyond': features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.

About Edison:

Edison is a content-led IR business. We believe quality investment content should inform all investors, not just brokers. Our mission: engage and build bigger, better-informed investor audiences for our clients.

Edison covers 50+ investment trusts, read about them here: https://www.edisongroup.com/equities/investment-companies/